ImmuCell Corporation Reports 4.3% Increase in Product Sales and Improved Gross Margin for Fiscal Year 2025

ImmuCell Corporation reported a notable financial performance for the fiscal year ending December 31, 2025, with product sales reaching $27.6 million, a 4.3% increase from $26.5 million in 2024. The company also improved its gross margin significantly from 30% to 41% of product sales, despite a non-cash write-off of certain inventories that accounted for approximately 2.4% of full-year product sales. The net operating income for 2025 was $1.6 million, a substantial recovery from a net operating loss of $1.6 million in the previous year. However, the company reported a net loss of $1.04 million, which was a 52% improvement compared to the $2.16 million loss in 2024.

In terms of operational developments, ImmuCell expanded its manufacturing capacity from 4.1 million units in 2024 to 4.6 million units in 2025. The company also eliminated a production backlog that had affected its operations in previous years. The strategic decision to focus on its First Defense® product line led to the cessation of further investment in the Re-Tain® product, resulting in a $2.7 million non-cash impairment charge. This pivot reflects the company's commitment to capitalize on the growing market for calf health solutions, particularly in the prevention of scours, which is a leading cause of mortality in neonatal calves.

The company has also made significant changes to its management structure, hiring a new President and Chief Executive Officer and creating a Chief Financial Officer position while eliminating the Vice President of Operations role. These changes are part of a broader strategy to enhance operational efficiency and drive growth in the First Defense® franchise. The company currently employs 73 individuals, focusing on quality, manufacturing, sales, and marketing.

ImmuCell's market presence continues to grow, with its First Defense® product line accounting for 99% of total product sales. The company estimates that its products are used to protect approximately 15% of calves on preventative programs, an increase from 13% in 2021. The total market for biological scours preventatives was valued at over $90 million in 2025, reflecting a 14% increase from the previous year. The company aims to increase its market share by expanding its commercial team and entering new international markets.

Looking ahead, ImmuCell plans to further enhance its First Defense® product line through innovation and increased manufacturing capacity. The company is optimistic about its growth prospects, particularly as it seeks to capture a larger share of the calf health market, where approximately 55% of U.S. calves remain unprotected by biological scours prevention products. The strategic focus on First Defense® is expected to drive future revenue growth and improve profitability, although the company acknowledges the inherent risks associated with market competition and regulatory approvals.